Prospects for engineering HIV-specific antibodies for enhanced effector function and half-life

Current Opinion in HIV and AIDS

Volumn 10, Issue 3, 2015, Pages 160-169

  Boesch, Austin W ^a   Alter, Galit ^b   Ackerman, Margaret E ^a,c  

^a DARTMOUTH COLLEGE   (United States)

^b HARVARD UNIVERSITY   (United States)

^c DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

antibody; effector function; immunoglobulin A; immunoglobulin G; Keywords antibody dependent cellular cytotoxicity; subclass

Indexed keywords

FC RECEPTOR; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; IMMUNOGLOBULIN FC FRAGMENT; NEUTRALIZING ANTIBODY;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY ENGINEERING; COMPLEMENT DEPENDENT CYTOTOXICITY; EFFECTOR CELL; GLYCOSYLATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; REVIEW; VACCINATION; VIRUS INHIBITION; ANIMAL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; MOUSE; PROTEIN ENGINEERING; PROTEIN STABILITY; RHESUS MONKEY;

ANIMALS; ANTIBODIES, NEUTRALIZING; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; MACACA MULATTA; MICE; PROTEIN ENGINEERING; PROTEIN STABILITY;

EID: 84928551656     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0000000000000149     Document Type: Review

References (72)

1. DiLillo DJ, Tan GS, Palese P, Ravetch JV. Broadly neutralizing hemagglutinin stalk-specific antibodies require FcgammaR interactions for protection against influenza virus in vivo. Nat Med 2014; 20:143-151.
2. Bournazos S, Chow SK, Abboud N, et al. Human IgG Fc domain engineering enhances antitoxin neutralizing antibody activity. J Clin Invest 2014; 124:725-729.
3. Varshney AK, Wang X, Aguilar JL, et al. Isotype switching increases efficacy of antibody protection against staphylococcal enterotoxin B-induced lethal shock and Staphylococcus aureus sepsis in mice. MBio 2014; 5:e01007-01014.
4. Furness AJ, Vargas FA, Peggs KS, Quezada SA. Impact of tumour microenvironment and Fc receptors on the activity of immunomodulatory antibodies. Trends Immunol 2014; 35:290-298.
5. Ratner M. Genentech's glyco-engineered antibody to succeed Rituxan. Nat Biotechnol 2014; 32:6-7.
6. Goede V, Fischer K, Busch R, et al.Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 2014; 370:1101-1110.
7. Qiu X, Wong G, Audet J, et al. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 2014; 514:47-53.
8. Johnson PR, Schnepp BC, Zhang J, et al. Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys. Nature medicine 2009; 15:901-906.
9. Bogers WM, Oostermeijer H, Mooij P, et al. Potent immune responses in rhesus macaques induced by nonviral delivery of a self-amplifying RNA vaccine expressing HIV type 1 envelope with a cationic nanoemulsion. J Infect Dis 2014.
10. Balazs AB, Chen J, Hong CM, et al. Antibody-based protection against HIV infection by vectored immunoprophylaxis. Nature 2012; 481:81-84.
11. Balazs AB, Ouyang Y, Hong CM, et al. Vectored immunoprophylaxis protects humanized mice from mucosal HIV transmission. Nature Med 2014; 20:296-300.
12. Horwitz JA, Halper-Stromberg A, Mouquet H, et al. HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice. Proc Natl Acad Sci U S A 2013; 110:16538-16543.
13. Klein F, Halper-Stromberg A, Horwitz JA, et al. HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. Nature 2012; 492:118-122.
14. Barouch DH, Whitney JB, Moldt B, et al. Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature 2013; 503:224-228.
15. Shingai M, Nishimura Y, Klein F, et al. Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia. Nature 2013; 503:277-280.
16. Klein F, Nogueira L, Nishimura Y, et al. Enhanced HIV-1 immunotherapy by commonly arising antibodies that target virus escape variants. J Exp Med 2014; 211:2361-2372.
17. Euler Z, Alter G. Exploring the potential of monoclonal antibody therapeutics for HIV-1 eradication. AIDS Res Hum Retroviruses 2015; 31:13-24.
18. Halper-Stromberg A, Lu CL, Klein F, et al. Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice. Cell 2014; 158:989-999.
19. Vidarsson G, Dekkers G, Rispens T. IgG subclasses and allotypes: from structure to effector functions. Front Immunol 2014; 5:520.
20. Davies AM, Rispens T, Ooijevaar-de Heer P, et al. Structural determinants of unique properties of human IgG4-Fc. J Mol Biol 2014; 426:630-644.
21. Liu H, May K. Disulfide bond structures of IgG molecules: structural variations, chemical modifications and possible impacts to stability and biological function. MAbs 2012; 4:17-23.
22. Diebolder CA, Beurskens FJ, de Jong RN, et al. Complement is activated by IgG hexamers assembled at the cell surface. Science 2014; 343:1260-1263.
23. Yang J, Goetze AM, Flynn GC. Assessment of naturally occurring covalent and total dimer levels in human IgG1 and IgG2. Mol Immunol 2014; 58:108-115.
24. Boruchov AM, Heller G, Veri MC, et al. Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions. J Clin Invest 2005; 115:2914-2923.
25. Yada A, Ebihara S, Matsumura K, et al. Accelerated antigen presentation and elicitation of humoral response in vivo by FcgammaRIIB-and FcgammaRI/IIImediated immune complex uptake. Cell Immunol 2003; 225:21-32.
26. Li X, Wu J, Ptacek T, et al. Allelic-dependent expression of an activating Fc receptor on B cells enhances humoral immune responses. Sc Transl Med 2013; 5:216ra175.
27. Ackerman ME, Alter G. Opportunities to exploit nonneutralizing HIV-specific antibody activity. Curr HIV Res 2013; 11:365-377.
28. Gillis C, Gouel-Cheron A, Jonsson F, Bruhns P. Contribution of human FcgammaRs to disease with evidence from human polymorphisms and transgenic animal studies. Front Immunol 2014; 5:254.
29. Ackerman ME, Nimmerjahn F. Antibody Fc: linking adaptive and innate immunity. 1st ed. Amsterdam; Burlington: Elsevier/Academic Press; 2014.
30. Arias JF, Heyer LN, von Bredow B, et al. Tetherin antagonism by Vpu protects HIV-infected cells from antibody-dependent cell-mediated cytotoxicity. Proc Natl Acad Sc U S A 2014; 111:6425-6430.
31. Gupta S, Gach JS, Becerra JC, et al. The neonatal Fc receptor (FcRn) enhances human immunodeficiency virus type 1 (HIV-1) transcytosis across epithelial cells. PLoS Pathog 2013; 9:e1003776.
32. Weflen AW, Baier N, Tang QJ, et al. Multivalent immune complexes divert FcRn to lysosomes by exclusion from recycling sorting tubules. Mol Biol Cell 2013; 24:2398-2405.
33. Ko SY, Pegu A, Rudicell RS, et al. Enhanced neonatal Fc receptor function improves protection against primate SHIV infection. Nature 2014; 514:642-645.
34. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009; 361:2209-2220.
35. Rolland M, Edlefsen PT, Larsen BB, et al. Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2. Nature 2012; 490:417-420.
36. Haynes BF, Gilbert PB, McElrath MJ, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 2012; 366:1275-1286.
37. Yates NL, Liao HX, Fong Y, et al. Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination. Sc Transl Med 2014; 6:228ra239.
38. Chung AW, Ghebremichael M, Robinson H, et al. Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccines. Sc Transl Med 2014; 6:228ra238.
39. Forthal DN, Gilbert PB, Landucci G, Phan T. Recombinant gp120 vaccineinduced antibodies inhibit clinical strains of HIV-1 in the presence of Fc receptor-bearing effector cells and correlate inversely with HIV infection rate. J Immunol 2007; 178:6596-6603.
40. Li SS, Gilbert PB, Tomaras GD, et al. FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial. J Clin Invest 2014; 124:3879-3890.
41. Ackerman ME, Crispin M, Yu X, et al. Natural variation in Fc glycosylation of HIV-specific antibodies impacts antiviral activity. J Clin Invest 2013; 123:2183-2192.
42. Ackerman ME, Dugast AS, McAndrew EG, et al. Enhanced phagocytic activity of HIV-specific antibodies correlates with natural production of immunoglobulins with skewed affinity for FcgammaR2a and FcgammaR2b. J Virol 2013; 87:5468-5476.
43. Dugast AS, Stamatatos L, Tonelli A, et al. Independent evolution of Fc-and Fab-mediated HIV-1-specific antiviral antibody activity following acute infection. Eur J Immunol 2014; 44:2925-2937.
44. Seaton KE, Ballweber L, Lan A, et al. HIV-1 specific IgA detected in vaginal secretions of HIV uninfected women participating in a microbicide trial in Southern Africa are primarily directed toward gp120 and gp140 specificities. PLoS One 2014; 9:e101863.
45. Hirbod T, Kong X, Kigozi G, et al. HIV acquisition is associated with increased antimicrobial peptides and reduced HIV neutralizing IgA in the foreskin prepuce of uncircumcised men. PLoS Pathog 2014; 10:e1004416.
46. Barouch DH, Liu J, Li H, et al. Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature 2012; 482:89-93.
47. Alpert MD, Heyer LN, Williams DE, et al. A novel assay for antibody-dependent cell-mediated cytotoxicity against HIV-1-or SIV-infected cells reveals incomplete overlap with antibodies measured by neutralization and binding assays. J Virol 2012; 86:12039-12052.
48. Barouch DH, Stephenson KE, Borducchi EN, et al. Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys. Cell 2013; 155:531-539.
49. Gomez-Roman VR, Patterson LJ, Venzon D, et al. Vaccine-elicited antibodies mediate antibody-dependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SIVmac251. J Immunol 2005; 174:2185-2189.
50. Moldt B, Shibata-Koyama M, Rakasz EG, et al. A nonfucosylated variant of the anti-HIV-1 monoclonal antibody b12 has enhanced FcgammaRIIIa-mediated antiviral activity in vitro but does not improve protection against mucosal SHIV challenge in macaques. J Virol 2012; 86:6189-6196.
51. Shang L, Smith AJ, Duan L, et al. NK cell responses to simian immunodeficiency virus vaginal exposure in naive and vaccinated rhesus macaques. J Immunol 2014; 193:277-284.
52. Li Q, Zeng M, Duan L, et al. Live simian immunodeficiency virus vaccine correlate of protection: local antibody production and concentration on the path of virus entry. J Immunol 2014; 193:3113-3125.
53. Smith AJ, Wietgrefe SW, Shang L, et al. Live simian immunodeficiency virus vaccine correlate of protection: immune complex-inhibitory Fc receptor interactions that reduce target cell availability. J Immunol 2014; 193:3126-3133.
54. Dugast AS, Chan Y, Hoffner M, et al. Lack of protection following passive transfer of polyclonal highly functional low-dose nonneutralizing antibodies. PLoS One 2014; 9:e97229.
55. Sholukh AM, Byrareddy SN, Shanmuganathan V, et al. Passive immunization of macaques with polyclonal anti-SHIV IgG against a heterologous tier 2 SHIV: outcome depends on IgG dose. Retrovirology 2014; 11:8.
56. Moog C, Dereuddre-Bosquet N, Teillaud JL, et al. Protective effect of vaginal application of neutralizing and nonneutralizing inhibitory antibodies against vaginal SHIV challenge in macaques. Mucosal Immunol 2014; 7:46-56.
57. Watkins JD, Siddappa NB, Lakhashe SK, et al. An anti-HIV-1 V3 loop antibody fully protects cross-clade and elicits T-cell immunity in macaques mucosally challenged with an R5 clade C SHIV. PLoS One 2011; 6:e18207.
58. Watkins JD, Sholukh AM, Mukhtar MM, et al. Anti-HIV IgA isotypes: differential virion capture and inhibition of transcytosis are linked to prevention of mucosal R5 SHIV transmission. AIDS 2013; 27:F13-20.
59. Smith P, DiLillo DJ, Bournazos S, et al. Mouse model recapitulating human Fcgamma receptor structural and functional diversity. Proc Natl Acad Sc U S A 2012; 109:6181-6186.
60. Pietzsch J, Gruell H, Bournazos S, et al. A mouse model for HIV-1 entry. Proc Natl Acad Sci U S A 2012; 109:15859-15864.
61. Bournazos S, Klein F, Pietzsch J, et al. Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity. Cell 2014; 158:1243-1253.
62. Boross P, Lohse S, Nederend M, et al. IgA EGFR antibodies mediate tumour killing in vivo. EMBO Mol Med 2013; 5:1213-1226.
63. Huls G, Heijnen IA, Cuomo E, et al. Antitumor immune effector mechanisms recruited by phage display-derived fully human IgG1 and IgA1 monoclonal antibodies. Cancer Res 1999; 59:5778-5784.
64. Brunke C, Lohse S, Derer S, et al. Effect of a tail piece cysteine deletion on biochemical and functional properties of an epidermal growth factor receptor-directed IgA2m(1) antibody. MAbs 2013; 5:936-945.
65. Lohse S, Derer S, Beyer T, et al. Recombinant dimeric IgA antibodies against the epidermal growth factor receptor mediate effective tumor cell killing. J Immunol 2011; 186:3770-3778.
66. Moldt B, Saye-Francisco K, Schultz N, et al. Simplifying the synthesis of SIgA: combination of dIgA and rhSC using affinity chromatography. Methods 2014; 65:127-132.
67. Lohse S, Brunke C, Derer S, et al. Characterization of a mutated IgA2 antibody of the m(1) allotype against the epidermal growth factor receptor for the recruitment of monocytes and macrophages. J Biol Chem 2012; 287:25139-25150.
68. Yoo EM, Trinh KR, Lim H, et al. Characterization of IgA and IgM binding and internalization by surface-expressed human Fcalpha/mu receptor. Mol Immunol 2011; 48:1818-1826.
69. Mimoto F, Katada H, Kadono S, et al. Engineered antibody Fc variant with selectively enhanced FcgammaRIIb binding over both FcgammaRIIa (R131) and FcgammaRIIa (H131). Protein Eng Des Sel 2013; 26:589-598.
70. Liu Z, Gunasekaran K,Wang W, et al. Asymmetrical Fc engineering greatly enhances antibody-dependent cellular cytotoxicity (ADCC) effector function and stability of the modified antibodies. J Biol Chem 2014; 289:3571-3590.
71. Derer S, Glorius P, Schlaeth M, et al. Increasing FcgammaRIIa affinity of an FcgammaRIII-optimized anti-EGFR antibody restores neutrophil-mediated cytotoxicity. MAbs 2014; 6:409-421.
72. Michaud HA, SenGupta D, de Mulder M, et al. Cutting edge: An antibody recognizing ancestral endogenous virus glycoproteins mediates antibodydependent cellular cytotoxicity on HIV-1-infected cells. J Immunol 2014; 193:1544-1548.